<DOC>
	<DOCNO>NCT01754493</DOCNO>
	<brief_summary>This study evaluate efficacy duloxetine reduce depressive symptom , abdominal pain , symptom Irritable Bowel Syndrome ( IRS ) population outpatient Major Depressive Disorder MDD clinical symptom IBS .</brief_summary>
	<brief_title>Open Trial Duloxetine Outpatients With Irritable Bowel Syndrome Symptoms Co-Morbid Major Depression</brief_title>
	<detailed_description>This study 12-week open trial ass efficacy duloxetine ( Cymbalta ) treatment Irritable Bowel Syndrome ( IBS ) symptoms comorbid Major Depressive Disorder ( MDD ) . Participants visit clinic 8 time meet psychiatrist . They receive duloxetine see help major depression Irritable Bowel symptom . Upon study completion 12 week , receive additional 3 month free medication treatment clinic .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Meets Diagnostic Statistical Manual , Fourth Edition ( DSMIV ) criteria major depressive disorder ( MDD ) Meets sufficient Rome III criterion clinical symptom IBS Able give consent Fluency English Spanish Patients age 5065 must provide negative colonoscopy report Current suicide risk History psychosis , bipolar disorder , current diagnosis ObsessiveCompulsive Disorder ( OCD ) History alcohol substance abuse dependence six month prior study History nonresponse adequate trial duloxetine Require concurrent treatment psychotropic medication psychiatric treatment , except zolpidem insomnia Receive current treatment monoamine oxidase inhibitor ( MAOI ) within 14 day visit 1 potential need use MAOI study within 5 day discontinuation study drug Patients uncontrolled narrowangle glaucoma Received electroconvulsive therapy ( ECT ) last three month Unable tolerate unwillingness accept drugfree period vary length : 1 week Pro Re Nata ( PRN ) benzodiazepines ; 2 week antidepressant ( fluoxetine ) , buspirone , lithium , anticonvulsant , stimulant , barbiturate , opiate , regularuse benzodiazepine ( except clonazepam ) ; 5 week clonazepam fluoxetine Clinically unstable medical disease include : Systemic hypertension 140/90 mm Hg ; know hypersensitivity duloxetine inactive ingredient ; liver function test value three time normal level ; clinically significant thyroid dysfunction , ( except patient stable thyroid replacement therapy least three month ) History chronic , persist vomiting ; rectal bleeding ( melena , hematochezia , Bright Red Blood Per Rectum ) ; severe , continuous abdominal pain ; nocturnal awakening GI symptom ; weight loss clearly relate decrease appetite MDD ; incapacitate symptom IBS ; severe Upper GI symptom ( e.g. , heartburn ) interrupt daily activity Family history Ulcerative Colitis , Crohn 's Disease , Celiac Disease Colon Cancer Clinical finding Physical Exam laboratory test : Rectal bleeding/obstruction , elevate White Blood Cell ( WBC ) count , unexplained anemia , abnormal Erythrocyte Sedimentation Rate ( ESR ) , abnormal celiac disease panel Evidence clinically significant renal , pulmonary , cerebral vascular , cardiovascular , endocrine disorder , prostatic hypertrophy , urinary retention , laboratory abnormality , abnormal electrocardiogram Cancer type . Patients remission 5 year may judge acceptable Patients current past history seizure disorder ( except febrile seizure childhood ) Patients pregnant , breastfeed use adequate contraceptive method . Adequate method include birth control pill , condom plus spermicide , intrauterine device , Norplant system , diaphragm . Patients receive effective medication depression IBS symptom . Patients effective medication either disorder exclude . Patients antidepressant and/or antiIBS medication intake must still meet inclusion criterion receive 3 month medication dose follow FDA guideline . Doses must raise produce either intolerable side effect treatment response . Patients require treatment thioridazine reason , baseline throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Major Depression</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Somatization</keyword>
	<keyword>Cymbalta</keyword>
	<keyword>Duloxetine</keyword>
</DOC>